Collaborative Agreements. In the event that any transfer of Penford's rights to Penwest under any of the Collaborative Agreements would violate or is found to violate the terms of, or result in the loss of rights or imposition of penalty under, any Collaborative Agreement covered thereby, or would not be effective subsequent to the Distribution Date, such transfer shall be deemed null and void and, in lieu thereof, (i) Penford shall retain all rights and fulfill any obligations, at Penwest's expense, it may have to any third party under any such Collaborative Agreement, it being understood that to the extent practicable, Penwest shall fulfill such obligations on Penford's behalf, (ii) Penford shall pay over to Penwest any royalty or other payments it may receive from any third party pursuant to any such Collaborative Agreement and (iii) at the request and expense of Penwest Penford shall use all reasonable best efforts to arrange for the grant by the applicable third party of comparable rights to Penwest.
Collaborative Agreements. Within two (2) months after the Effective Date, the Pfizer Program Leader shall direct COLEY, in writing, to terminate or assign to PFIZER, to the extent assignment is permissible, each ongoing Third Party collaborative agreement relating to the Compound, including without limitation material transfer agreements and supported research agreements. After the Effective Date, COLEY shall not enter into any new collaborative agreement, or amend any such existing agreement to provide any additional funding (including without limitation the Compound or any clinical supplies), without the express written consent of the Pfizer Program Leader.
Collaborative Agreements. Provide the Issuer and the Bank with summaries of any collaborative agreements as may be qualified by confidentiality agreement within 30 days after the effective date of such agreement or agreements.
Collaborative Agreements. When appropriate, the Parties shall enter into legally binding collaborative agreements, or such other agreements as necessary for each proposed collaborative project on terms to be negotiated. Financial arrangements Each Party will be solely responsible for the administration and expenditure of its own resources associated with activities conducted under this MoU.
Collaborative Agreements a. Contractor shall provide DSHS copies of written agreements, including budgets, with all vendors and subrecipient contractors identified in approved response to Request for Proposal (RFP)#: 000-00-0000. Contractor shall notify DSHS in writing and request prior approval to terminate an existing vendor or subrecipient contract. Contractor shall provide DSHS copies of Memoranda of Understanding (MOUs) and/or other written agreements with other service providers within the collaborative project that are providing Minimum/Required Program Specific Services and/or Optional/Additional Program Specific Services that benefit collaborative project participants upon execution of those MOUs and/or other written agreements. Contractor shall notify DSHS in writing if service providers are removed from the collaborative project upon termination of any existing MOU or other written agreement.
Collaborative Agreements. This Agreement provides the overall framework for the Collaborative, and contemplates the execution of the additional Collaborative Agreements summarized below to address in greater detail specific areas affecting the Collaborative. Unless otherwise expressly agreed by the Parties in writing, execution of each of the additional Collaborative Agreements prior to the Commencement Date is a condition precedent to this Agreement and the failure to execute one or more of the Collaborative Agreements by the Commencement Date shall be cause for termination of this Agreement. Each of the Collaborative Agreements, including, without limitation, the New CEA, will be implemented and administered consistent with the Governing Principles. Subject to the wind down procedures set forth in Article 11, termination or expiration of this Agreement in accordance with its terms will automatically result in termination of all the additional Collaborative Agreements. In case of conflict between the terms of this Agreement and any other Collaborative Agreement, the terms of this Agreement will control.
Collaborative Agreements. (a) The Provider agrees not to enter into a collaborative agreement with any third party unless in compliance with this Section 11. For these purposes, a Collaborative Agreement is a written agreement between the Provider and a third party ("Non-4410 Program"), including a third party that is in a less-than-arm's-length relationship with the Provider, to effect the implementation of the Provider's approved Special Class in an Integrated Setting ("SCIS") program, regardless whether monetary consideration is involved.
Collaborative Agreements. (a) If the collaborative agreement is approved by the board under (d) of this section, a dental hygienist with a minimum of 4,000 documented hours of clinical experience within the five years preceding application for the board's approval may enter into a collaborative agreement with a dentist licensed under AS 08.36 in which the licensed dentist authorizes the dental hygienist to perform one or more of the following:
Collaborative Agreements. MPI and MBI each recognize that the other party intends to enter into collaboration agreements, strategic alliances, license agreements and similar arrangements with Collaborative Partners (a "Collaboration Agreement"). MPI and MBI each agree to use reasonable efforts in negotiating such arrangements to limit the licenses and rights granted to a Collaborative Partner to the MPI Core Field and MBI Core Field, respectively. However, (i) in the event that ***, ** *********** * ************* *********, ******** ** **** ***** that the ******* ** include in such ********* ****** *** ******** ** *** *** **** ***** ** ********** ********* pursuant to the Collaboration Agreement would have a ******** ****** ** ****** *** *********** ** *** ************* ******* ** ***** **** * ************* ********* ** *** ********* ***** *******, **** *** ***, ***** ********* *** ** ******* *** ********** ** ** ********* ***** **** *** *** ***** ******** to the ******** ************* *********, ***** **** **** ************* ********* and the provisions of subsection (a) shall *** ***** ** *** ******** *** ****** ** *******, provided that the ***** ** **** ******** *** ****** ******* *** *** **** ***** ** ********** ** * **** **** ********* ********** ** *** *** **** *****; and (ii) in the ***** **** ***, ** *********** * ************* *********, ******** ** **** ***** that the ******* ** ******* ** **** ********* ****** *** ******** ** *** *** **** ***** ** ********** ********* ******** ** *** ************* ********* would have a ******** ****** ** ****** *** *********** ** *** ************* ******* ** ***** **** *** ************* ********* ** *** ********* ***** *******, **** *** ***, ***** ********* *** ** ******* *** ********** ** ** ********* ***** **** *** *** ***** ******** to the ******** ************* *********, ***** **** **** ************* ********* and the provisions of subsection (b) shall *** ***** ** *** ******** *** ****** ** *******, provided that the ***** ** **** ******** *** ****** ** ********** ** * **** **** ********* ********** ** *** *** **** *****.
Collaborative Agreements. In May 1999, Aradigm signed an agreement with Genentech to develop the drug dornase alfa in the AERx system. Dornase alfa is the active ingredient in the currently marketed Genentech product, Pulmozyme. The agreement provides that development expenses incurred by Aradigm will be reimbursed by Genentech in the form of loans supported by promissory notes bearing interest at two percent over the prime rate which was 10.5% at December 31, 1999. Principal and unpaid accrued interest is due at the earlier of 15 days after FDA approval or seven years after the effective date of the collaborative agreement or May 21, 2006. Upon receipt of FDA approval, Aradigm will receive a milestone payment that is larger than the loan principal and accrued interest, allowing the loan to be repaid in full. The Company will also receive certain milestone payments at various points of product development. In June 1998, the Company executed a development and commercialization agreement with Novo Nordisk to jointly develop a pulmonary delivery system for administering insulin by inhalation. In addition, the agreement provides Novo Nordisk with an option to develop the technology for delivery of other compounds. Under the terms of the agreement, Novo Nordisk has been granted exclusive rights to worldwide sales and marketing rights to any products developed under the terms of the agreement. In 1999, pursuant to the Novo Nordisk agreement, Aradigm had received approximately $13.9 million milestone and product development payments and could receive up to $34 million in additional milestone payments and a $5.0 million equity investment. In 1998, Aradigm received approximately $13.5 million, including the purchase of $5.0 million of newly issued Aradigm common stock at a 25% premium to the market price. In addition, Novo Nordisk will fund all product development costs incurred by Aradigm, while the development partners will co-fund final development of the AERx device. Aradigm will be the initial manufacturer of all the products covered by the agreement and will receive a share of the overall gross profits resulting from Novo Nordisk's sales of the products. Through December 31, 1999, the Company has recognized total contract revenue of $14.0 million ($8.7 million and $5.3 million in 1999 and 1998, respectively). In September 1997, the Company executed a development and commercialization agreement with SmithKline Xxxxxxx covering use of the AERx Pain Management System for the delivery of ...
